PolymarketKullanılabilirliği kontrol etKYC yok%2 ücretGüncel ima edilen olasılıkEvet 12%-0.0%
Piyasa kalitesi
52 / 100
Orta kalite24s Hacim
₺12,7 B
Likidite
₺137,3 B
Orta likiditeAlis / Satis
11.0% / 12.0%
Spread
9.1%
Geniş spread7g Değişim
-4.5%
Piyasa verileri
5 dakika önce guncellendi
12 Oca 26 23:0931 Ara 26 0:00
Trendler
Seçilen sonuç
Yes12%
Kalshi üzerinde de mevcut
Will the FDA approve retatrutide?
11.0%6ay
-11.0%17%
-7.0%85%
-7.0%87%
+2 daha fazla sonuç
28 • Düşük kaliteGeniş spreadDüşük likiditeSığ piyasa
Toplam Hacim₺5,4 B
24s Hacim₺272,2
KALSHIKurallar
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.
- This market will resolve to "Yes" if the U.S.
- Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
Olasılıklar farklı piyasa yapıları, ücretler ve katılımcı havuzları nedeniyle değişiklik gösterebilir.
İlgili Piyasalar
Hantavirus pandemic in 2026?
₺7,9 MnEvet: 5%POLYMARKET
POLYMARKET
New pandemic in 2026?
₺886,9 BEvet: 10%POLYMARKET
POLYMARKET
Ebola pandemic in 2026?
₺468,2 BEvet: 8%POLYMARKET
POLYMARKET
How many movies will gross >$1 billion in 2026?
₺67,1 B0-3: 5.7%MANIFOLD MARKETS
MANIFOLD MARKETSWhich disease will be eradicated next in humans?
₺24,7 BPolio: 26.7%MANIFOLD MARKETS
MANIFOLD MARKETSBu konularda aktif
İlgili Haberler
Chainalysis reveals $100 million peptide market built on cryptoCrypto News
Gray peptide vendors embrace stablecoins as safety fears deepenCrypto News
OpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.News
Brian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto NewsKurallar
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.
- This market will resolve to "Yes" if the U.S.
- Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs